{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:55:52Z","timestamp":1783724152488,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04202-1","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T03:26:39Z","timestamp":1741836399000},"page":"820-825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of pasireotide in patients with Cushing\u2019s disease: a monocentric experience"],"prefix":"10.1007","volume":"88","author":[{"given":"Ylenia","family":"Alessi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Alibrandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo Flavio","family":"Angileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ferrau\u0300","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cannavo\u0300","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"12","key":"4202_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"M Fleseriu, R Auchus, I Bancos, A Ben-Shlomo, J Bertherat, N.R Biermasz, C.L Boguszewski, M.D Bronstein, M Buchfelder, J.D Carmichael, F.F Casanueva, F Castinetti, P Chanson, J Findling, M Gadelha, E.B Geer, A Giustina, A Grossman, M Gurnell, K Ho, A.G Ioachimescu, U.B Kaiser, N Karavitaki, L Katznelson, D.F Kelly, A Lacroix, A McCormack, S Melmed, M Molitch, P Mortini, J Newell-Price, L Nieman, A.M Pereira, S Petersenn, R Pivonello, H Raff, M Reincke, R Salvatori, C Scaroni, I Shimon, C.A Stratakis, B Swearingen, A Tabarin, Y Takahashi, M Theodoropoulou, S Tsagarakis, E Valassi, E.V Varlamov, G Vila, J Wass, S.M Webb, M.C Zatelli, B.M.K Biller, Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12), 847\u2013875 (2021). https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"4202_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2021.104091","volume":"50","author":"A Ferriere","year":"2021","unstructured":"A Ferriere, A Tabarin, Cushing\u2019s disease. Presse Med 50(4), 104091 (2021). https:\/\/doi.org\/10.1016\/j.lpm.2021.104091.","journal-title":"Presse Med"},{"key":"4202_CR3","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3389\/fendo.2020.00648","volume":"11","author":"R Pivonello","year":"2020","unstructured":"R. Pivonello, R. Ferrigno, M.C. De Martino, C. Simeoli, N. Di Paola, C. Pivonello, L. Barba, M. Negri, C. De Angelis, A. Colao, Medical treatment of Cushing\u2019s disease: an overview of the current and recent clinical trials. Front Endocrinol (Lausanne) 11, 648 (2020). https:\/\/doi.org\/10.3389\/fendo.2020.00648","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"4202_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11154-022-09710-3","volume":"23","author":"M Bolanowski","year":"2022","unstructured":"M Bolanowski, M Ka\u0142u\u017cny, P Witek, A Jawiarczyk-Przyby\u0142owska, Pasireotide-a novel somatostatin receptor ligand after 20 years of use. Rev Endocr Metab Disord 23(3), 601\u2013620 (2022). https:\/\/doi.org\/10.1007\/s11154-022-09710-3.","journal-title":"Rev Endocr Metab Disord"},{"key":"4202_CR5","doi-asserted-by":"publisher","unstructured":"R Pivonello, S Petersenn, J Newell-Price, J.W Findling, F Gu, M Maldonado, A Trovato, G Hughes, L.R Salgado, A Lacroix, J Schopohl, B.M Biller, Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a Phase III study. Clin Endocrinol (Oxf) 81(3), 408\u2013417 (2014). Pasireotide B2305 Study Group. https:\/\/doi.org\/10.1111\/cen.12431.","DOI":"10.1111\/cen.12431"},{"issue":"1","key":"4202_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12020-018-1524-5","volume":"61","author":"A Albani","year":"2018","unstructured":"A Albani, F Ferra\u00f9, A Ciresi, R Pivonello, C Scaroni, D Iacuaniello, M Zilio, V Guarnotta, A Alibrandi, E Messina, M Boscaro, C Giordano, A Colao, S Cannavo, Pasireotide treatment reduces cardiometabolic risk in Cushing\u2019s disease patients: an Italian, Multicenter study. Endocrine 61(1), 118\u2013124 (2018). https:\/\/doi.org\/10.1007\/s12020-018-1524-5.","journal-title":"Endocrine"},{"key":"4202_CR7","doi-asserted-by":"publisher","unstructured":"C. Simeoli, R.S. Auriemma, F. Tortora, M. De Leo, D. Iacua-niello, A. Cozzolino, M.C. De Martino, C. Pivonello, C.G. Mainolfi, R. Rossi, S. Cirillo, A. Colao, R. Pivonello, Erratum to: the treatment with pasireotide in Cushing\u2019s disease: effects of long-term treatment on tumor mass in the experience of a single center. Endocrine 53(1), 339\u2013341 (2016). https:\/\/doi.org\/10.1007\/s12020-016-0924-7. Erratum for: Endocrine. 2015 Dec;50(3):725-40. https:\/\/doi.org\/10.1007\/s12020-015-0557-2","DOI":"10.1007\/s12020-016-0924-7"},{"issue":"3","key":"4202_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s12020-018-1818-7","volume":"64","author":"R Pivonello","year":"2019","unstructured":"R Pivonello, G Arnaldi, C Scaroni, C Giordano, S Cannav\u00f2, D Iacuaniello, L Trementino, M Zilio, V Guarnotta, A Albani, A Cozzolino, G Michetti, M Boscaro, A Colao, The medical treatment with pasireotide in Cushing\u2019s disease: an Italian multicentre experience based on \u201creal-world evidence\u201d. Endocrine 64(3), 657\u2013672 (2019). https:\/\/doi.org\/10.1007\/s12020-018-1818-7.","journal-title":"Endocrine"},{"issue":"5","key":"4202_CR9","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s11102-016-0734-1","volume":"19","author":"JM Silverstein","year":"2016","unstructured":"J.M Silverstein, Hyperglycemia induced by pasireotide in patients with Cushing\u2019s disease or acromegaly. Pituitary 19(5), 536\u2013543 (2016). https:\/\/doi.org\/10.1007\/s11102-016-0734-1.","journal-title":"Pituitary"},{"issue":"11","key":"4202_CR10","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"M Fleseriu, I.A Hashim, N Karavitaki, S Melmed, M.H Murad, R Salvatori, M.H Samuels, Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(11), 3888\u20133921 (2016). https:\/\/doi.org\/10.1210\/jc.2016-2118.","journal-title":"J Clin Endocrinol Metab"},{"key":"4202_CR11","doi-asserted-by":"publisher","unstructured":"N.A. ElSayed, G. Aleppo, V.R. Aroda, R.R. Bannuru, F.M. Brown, D. Bruemmer, B.S. Collins, M.E. Hilliard, D. Isaacs, E.L. Johnson, S. Kahan, K. Khunti, J. Leon, S.K. Lyons, M.L. Perry, P. Prahalad, R.E. Pratley, J.J. Seley, R.C. Stanton, R.A. Gabbay; American Diabetes Association, 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes care 2023;46(Suppl. 1):S19-S40. Diabetes Care 46(9), 1715 (2023). https:\/\/doi.org\/10.2337\/dc23-ad08. Erratum for: Diabetes Care. 2023 Jan 1;46(Suppl 1):S19-S40. https:\/\/doi.org\/10.2337\/dc23-S002","DOI":"10.2337\/dc23-ad08"},{"key":"4202_CR12","doi-asserted-by":"publisher","unstructured":"JA. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller; Pasireotide B2305 Study Group, A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366(10), 914\u2013924 (2012). https:\/\/doi.org\/10.1056\/NEJMoa1105743. Erratum in: N Engl J Med. 2012 Aug 23;367(8):780","DOI":"10.1056\/NEJMoa1105743"},{"issue":"5","key":"4202_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","volume":"18","author":"J Schopohl","year":"2015","unstructured":"J Schopohl, F Gu, R Rubens, LVan Gaal, J Bertherat, M Ligueros-Saylan, A Trovato, G Hughes, L.R Salgado, M Boscaro, R Pivonello; Pasireotide B2305 Study Group, Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing\u2019s disease: results from an open-ended, open-label extension trial. Pituitary 18(5), 604\u2013612 (2015). https:\/\/doi.org\/10.1007\/s11102-014-0618-1.","journal-title":"Pituitary"},{"issue":"1","key":"4202_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12020-017-1316-3","volume":"57","author":"S Petersenn","year":"2017","unstructured":"S Petersenn, L.R Salgado, J Schopohl, L Portocarrero-Ortiz, G Arnaldi, A Lacroix, C Scaroni, S Ravichandran, A Kandra, B.M.K Biller, Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine 57(1), 156\u2013165 (2017). https:\/\/doi.org\/10.1007\/s12020-017-1316-3.","journal-title":"Endocrine"},{"key":"4202_CR15","unstructured":"N.C. Olarescu, K. Gunawardane, T.K. Hansen, N. M\u00f8ller, J.O.L. J\u00f8rgensen Normal physiology of growth hormone in adults. 2019 Oct 16. In: K.R. Feingold, B. Anawalt, M.R. Blackman, A. Boyce, G. Chrousos, E. Corpas, W.W. de Herder, K. Dhatariya, K. Dungan, J. Hofland, S. Kalra, G. Kaltsas, N. Kapoor, C. Koch, P. Kopp, M. Korbonits, C.S. Kovacs, W. Kuohung, B. Laferr\u00e8re, M. Levy, E.A. McGee, R. McLachlan, M. New, J. Purnell, R. Sahay, A.S. Shah, F. Singer, M.A. Sperling, C.A. Stratakis, D.L. Trence, D.P. Wilson, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000"},{"key":"4202_CR16","doi-asserted-by":"publisher","unstructured":"A. Lacroix, F. Gu, W. Gallardo, R. Pivonello, Y. Yu, P. Witek, M. Boscaro, R. Salvatori, M. Yamada, L. Tauchmanova, M. Roughton, S. Ravichandran, S. Petersenn, B.M.K. Biller, J. Newell-Price; Pasireotide G2304 Study Group, Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 6(1), 17\u201326 (2018). https:\/\/doi.org\/10.1016\/S2213-8587(17)30326-1. Epub 2017 Oct 12Erratum in: Lancet Diabetes Endocrinol. 2018 Jan;6(1):e1. https:\/\/doi.org\/10.1016\/S2213-8587(17)30410-2","DOI":"10.1016\/S2213-8587(17)30326-1"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04202-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T13:05:28Z","timestamp":1749215128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04202-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["4202"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04202-1","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}